JSKN003 not checked

JMT-Bio

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
7 active
8 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“JSKN003 (6.3 mg/kg) was administered intravenously on the first day of each cycle, once every 3 weeks (Q3W).”In the company’s words, NCT07384377 on ClinicalTrials.gov
Tested for
Breast Cancer, Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants, Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers, HER2-positive Colorectal Cancer, HER2-positive Recurrent or Metastatic Breast Cancer, HER2-positive Gastric Cancer and 1 more
Main trialPhase 3
“This study is a randomized controlled, open-label, multicenter phase III clinical study evaluating the efficacy and safety of chemotherapy selected by investigator JSKN003 s in subjects with recurrent or metastatic breast cancer who have previously failed first- or second-line chemotherapy in subjects with recurrent or metastatic breast cancer who have failed prior first- or second-line chemotherapy. The study planned to enroll 408 subjects in a 1:1 ratio and stratified block randomization method assigned to: * Experimental group: JSKN003 monotherapy * Control group: investigator's chosen…”In the company’s words, NCT06079983 on ClinicalTrials.gov

Other drugs for Breast Cancer

All 396 drugs for Breast Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 1 Apr 2026 JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Phase 3Recruiting 13 Oct 2026 JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Phase 3Not yet recruiting 30 Dec 2026 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Phase 3Not yet recruiting 30 Nov 2027 JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Phase 2Not yet recruiting 29 May 2027 A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Phase 2Not yet recruiting 30 Jun 2028 JSKN003 Combined Treatment of HER2-positive Gastric Cancer
Phase 1/2Active, not recruiting 30 Jul 2026 Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Phase 1Completed 15 Apr 2025 First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow JSKN003

Following is part of Solo: you see every change to JSKN003 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in